In addition to backend improvements which will enable more frequent release cycles, future work focuses on the integration of available data sets for more diverse populations. This includes international biobanks and population studies as they become publicly available, as well as developing LD matrices for non-European populations to allow GWAS catalog and Biobank data for these populations to be analysed. We plan to integrate COVID-19 infection susceptibility genetic study results as these become available, to aid in the drug discovery effort for the global pandemic by providing supporting genetic evidence for key human target genes. We also plan to develop existing features, such as expanding the colocalisation view to be genome-wide.
